Halogen treatment of heart attack and ischemic injury
The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
1. A method for inhibiting a reperfusion injury in a subject, comprising administering sodium iodide to the subject, wherein the subject is a mammal.
2. The method of claim 1 , wherein the subject has undergone a heart attack prior to the administering of sodium iodide to the subject.
3. The method of claim 2 , wherein the heart attack is an ST-segment elevation myocardial infarction.
4. The method of claim 1 , wherein the reperfusion injury results from a primary percutaneous coronary intervention.
5. The method of claim 1 , wherein the reperfusion injury results from a thrombolysis.
6. The method of claim 1 , wherein the reperfusion injury results from a coronary bypass surgery.
7. The method of claim 6 , wherein the coronary bypass surgery is a coronary artery bypass graft.
8. The method of claim 1 , wherein the reperfusion injury results from a primary percutaneous coronary intervention following a heart attack.
9. The method of claim 8 , wherein the heart attack is an ST-segment elevation myocardial infarction.
10. The method of claim 1 , wherein the sodium iodide is administered parenterally.
11. The method of claim 10 , wherein the sodium iodide is administered intravenously or by infusion.
12. The method of claim 1 , wherein the subject is administered an amount of sodium iodide sufficient to increase the blood concentration of iodide at least 500%.
13. A method for inhibiting a reperfusion injury in a subject, wherein the reperfusion injury results from a primary percutaneous coronary intervention following an ST-segment elevation myocardial infarction, the method comprising administering sodium iodide to the subject, wherein the sodium iodide is administered intravenously or by infusion, and wherein the subject is a mammal.
14. A method for inhibiting heart failure in a subject, comprising administering sodium iodide to the subject, wherein the subject is a mammal.
15. The method of claim 14 , wherein the heart failure results from a heart attack.
16. The method of claim 15 , wherein the heart attack is an ST-segment elevation myocardial infarction.
17. The method of claim 14 , wherein the heart failure results from reperfusion injury following a primary percutaneous coronary intervention.
18. The method of claim 14 , wherein the heart failure results from reperfusion injury following a primary percutaneous coronary intervention following a heart attack.
19. The method of claim 18 , wherein the heart attack is an ST-segment elevation myocardial infarction.
20. The method of claim 14 , wherein the sodium iodide is administered parenterally.
21. The method of claim 20 , wherein the sodium iodide is administered intravenously or by infusion.
22. The method of claim 14 , wherein the subject is administered an amount of sodium iodide sufficient to increase the blood concentration of iodide at least 500%.